Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(15):1116-1117; doi:10.1093/jnci/djh247
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Grem, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grem, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

EDITORIAL

Adjuvant Therapy for Colon Cancer: A Historical Perspective

Jean Grem

Correspondence to: Jean Grem, MD, Section of Oncology/Hematology, Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-7680 (e-mail: jgrem@unmc.edu)

The first 10% of the full text of this article appears below.

In this issue, Smith et al. (1) present the 10-year results of the first National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol for colon cancer. The three-armed trial randomly assigned 1166 patients with Dukes’ stage B and C colon cancer to surgery alone; postoperative chemotherapy with eight 10-week cycles of semustine, 5-fluorouracil, and vincristine (MOF); or postoperative immunotherapy with bacillus Calmette-Guérin (BCG) given weekly for 12 weeks and then every other week for a total of 45 doses. When the initial results were published in 1988 (2), adjuvant MOF therapy was associated with a statistically significant improvement in disease-free survival (58% versus 51%; P . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
D. G. Nicastri, J. T. Doucette, T. E. Godfrey, and S. J. Hughes
Is Occult Lymph Node Disease in Colorectal Cancer Patients Clinically Significant?: A Review of the Relevant Literature
J. Mol. Diagn., November 1, 2007; 9(5): 563 - 571.
[Abstract] [Full Text] [PDF]